Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor

Abstract

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.